+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaccine Adjuvants Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product Type, Route of Administration, Disease Type, Application, Vaccine Type, End User, Geographic Coverage and By Company)

  • PDF Icon

    Report

  • 182 Pages
  • January 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 6051457
Description Jump to:

The global vaccine adjuvants market is poised for significant expansion, with projections estimating a market value of US$ 4.33 Bn by 2032, growing from US$ 1.69 Bn in 2025. The market is expected to witness a CAGR of 14.3% from 2025 to 2032, driven by rising infectious diseases and continuous advancements in vaccine adjuvant technologies.

Market Insights

  • The growing burden of infectious diseases such as COVID-19, malaria, and dengue has intensified the need for effective vaccines, fueling demand for advanced adjuvants.
  • Innovations in lipid nanoparticles and immune modulators are enhancing vaccine efficacy and safety.
  • The increasing adoption of mRNA vaccine technology, which relies heavily on novel adjuvants, is a key market driver.
  • Government funding and immunization programs are facilitating the development and adoption of new adjuvants.
  • Pharmaceutical companies are investing significantly in novel adjuvant research to combat emerging pathogens.
  • Regulatory approvals from agencies such as FDA and EMA play a crucial role in market expansion.
  • The shift toward personalized vaccines creates opportunities for tailored adjuvants targeting specific patient groups.

Key Market Drivers

Rising Prevalence of Infectious Diseases

  • Increasing incidences of influenza, malaria, dengue, and COVID-19 are driving demand for improved vaccine formulations.
  • In 2024, over 14 million dengue cases and more than 10,000 dengue-related deaths were reported worldwide.
  • Vector-borne diseases contribute to over 17% of all infectious diseases, causing approximately 700,000 deaths annually.
  • Vaccine adjuvants enhance immune responses, ensuring long-lasting and comprehensive protection.

Government Immunization Programs and Funding

  • Governments worldwide are increasing investments in immunization programs, accelerating the adoption of vaccine adjuvants.
  • Organizations such as WHO, UNICEF, and Gavi support large-scale vaccination campaigns, particularly in underserved regions.
  • Programs like Gavi, the Vaccine Alliance, are ensuring vaccine availability in low-income countries.
  • Governments are expanding public health budgets and grant allocations to pharmaceutical companies for vaccine research and production.

Market Opportunities

Development of Novel Adjuvants

Vaccine manufacturers are focusing on the development of next-generation adjuvants, such as:

  • Lipid nanoparticles (LNPs)
  • Liposomes
  • Immune modulators
  • These novel adjuvants improve immune response, especially against emerging infectious diseases.

Expansion of mRNA Vaccine Technology

  • mRNA vaccine technology is revolutionizing the vaccine adjuvants market, with successful applications in COVID-19 vaccines.
  • Lipid nanoparticles (LNPs) are widely used in mRNA vaccines to enhance delivery and immune stimulation.
  • In 2024, the U.S. government allocated US$ 590 Mn to Moderna for the development of an mRNA-based H5N1 avian influenza vaccine.
  • The increasing use of mRNA vaccines for diseases like influenza, Zika virus, and cancer is expected to boost demand for adjuvants.

Regional Analysis

North America: Market Leader

North America dominates the global vaccine adjuvants market due to:

  • Advanced healthcare infrastructure
  • Significant investments in R&D
  • Government-led immunization programs
  • Strong presence of pharmaceutical companies
  • The region is a hub for cutting-edge vaccine research and novel adjuvant development.

Asia Pacific: Fastest-Growing Market

Asia Pacific is emerging as a major market, driven by:

  • Government-led vaccination programs in China, India, and Japan
  • Rising healthcare expenditures
  • Growing pharmaceutical and biotechnology sectors
  • High prevalence of infectious diseases
  • The region’s large population base and improving healthcare infrastructure make it a lucrative market for vaccine adjuvants.

Competitive Analysis

The vaccine adjuvants market is highly competitive, with leading companies focusing on product innovation and portfolio expansion. Key players are developing next-generation adjuvants to enhance vaccine efficacy.

Key Market Players

1. Pfizer Inc.
2. GlaxoSmithKline plc
3. AstraZeneca
4. 3M
5. Merck KGaA
6. Adjuvatis
7. Croda International Plc
8. Novavax, Inc.
9. InvivoGen
10. Phibro Animal Health Corporation
11. SEPPIC
12. Agenus Inc.

Recent Industry Developments

  • June 2024 - SPI Pharma, Inc. and Inimmune, Corp. partnered to commercialize new vaccine adjuvant systems.
  • March 2024 - Croda International Plc collaborated with Access to Advanced Health Institute (AAHI) to develop innovative adjuvant formulations.

Market Segmentation

By Product Type

  • Adjuvant Emulsions (30% share in 2025)
  • Particulate Adjuvants
  • Combination Adjuvants
  • Pathogen Components
  • Carbohydrate Adjuvants
  • Liposome Adjuvants
  • Alum
  • Others

By Route of Administration

  • Intramuscular Route
  • Intranasal Route
  • Intradermal Route
  • Oral Route
  • Subcutaneous Route
  • Others

By Disease Type

  • Infectious Diseases
  • Cancer
  • Others

By Application

  • Commercial Application
  • Research Application

By Vaccine Type

  • Human Vaccine (70% share in 2025)
  • Veterinary Vaccine

By End User

  • Adults
  • Pediatric
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Vaccine Adjuvant Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Price Analysis, 2019 - 2025
3.1. Global Average Price Analysis, by Product Type, US$ Per Unit, 2019 - 2032
3.2. Prominent Factor Affecting Vaccine Adjuvant Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit
4. Global Vaccine Adjuvant Market Outlook, 2019 - 2032
4.1. Global Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.1.1. Key Highlights
4.1.1.1. Adjuvant emulsions
4.1.1.2. Particulate adjuvants
4.1.1.3. Combination adjuvants
4.1.1.4. Pathogen components
4.1.1.5. Carbohydrate adjuvants
4.1.1.6. Liposome adjuvants
4.1.1.7. Alum
4.1.1.8. Others
4.2. Global Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.2.1. Key Highlights
4.2.1.1. Intramuscular Route
4.2.1.2. Intranasal Route
4.2.1.3. Intradermal Route
4.2.1.4. Oral Route
4.2.1.5. Subcutaneous Route
4.2.1.6. Others
4.3. Global Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.3.1. Key Highlights
4.3.1.1. Cancer
4.3.1.2. Infectious diseases
4.3.1.3. Others
4.4. Global Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.4.1. Key Highlights
4.4.1.1. Commercial application
4.4.1.2. Research application
4.5. Global Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.5.1. Key Highlights
4.5.1.1. Human vaccine
4.5.1.2. Veterinary vaccine
4.6. Global Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.6.1. Key Highlights
4.6.1.1. Adults
4.6.1.2. Pediatric
4.6.1.3. Others
4.7. Global Vaccine Adjuvant Market Outlook, by Region, Value (US$ Bn) and Volume (Units), 2019 - 2032
4.7.1. Key Highlights
4.7.1.1. North America
4.7.1.2. Europe
4.7.1.3. Asia Pacific
4.7.1.4. Latin America
4.7.1.5. Middle East & Africa
5. North America Vaccine Adjuvant Market Outlook, 2019 - 2032
5.1. North America Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Adjuvant emulsions
5.1.1.2. Particulate adjuvants
5.1.1.3. Combination adjuvants
5.1.1.4. Pathogen components
5.1.1.5. Carbohydrate adjuvants
5.1.1.6. Liposome adjuvants
5.1.1.7. Alum
5.1.1.8. Others
5.2. North America Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Intramuscular route
5.2.1.2. Intranasal route
5.2.1.3. Intradermal route
5.2.1.4. Oral route
5.2.1.5. Subcutaneous route
5.2.1.6. Others
5.3. North America Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. Cancer
5.3.1.2. Infectious diseases
5.3.1.3. Others
5.4. North America Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.4.1. Key Highlights
5.4.1.1. Commercial application
5.4.1.2. Research application
5.5. North America Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.5.1. Key Highlights
5.5.1.1. Human vaccine
5.5.1.2. Veterinary vaccine
5.6. North America Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.6.1. Key Highlights
5.6.1.1. Adults
5.6.1.2. Pediatric
5.6.1.3. Others
5.7. North America Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1. Key Highlights
5.7.1.1. U.S. Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.2. U.S. Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.3. U.S. Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.4. U.S. Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.5. U.S. Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.6. U.S. Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.7. Canada Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.8. Canada Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.9. Canada Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.10. Canada Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.11. Canada Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
5.7.1.12. Canada Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6. Europe Vaccine Adjuvant Market Outlook, 2019 - 2032
6.1. Europe Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Adjuvant emulsions
6.1.1.2. Particulate adjuvants
6.1.1.3. Combination adjuvants
6.1.1.4. Pathogen components
6.1.1.5. Carbohydrate adjuvants
6.1.1.6. Liposome adjuvants
6.1.1.7. Alum
6.1.1.8. Others
6.2. Europe Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Intramuscular route
6.2.1.2. Intranasal route
6.2.1.3. Intradermal route
6.2.1.4. Oral route
6.2.1.5. Subcutaneous route
6.2.1.6. Others
6.3. Europe Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. Cancer
6.3.1.2. Infectious diseases
6.3.1.3. Others
6.4. Europe Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.4.1. Key Highlights
6.4.1.1. Commercial application
6.4.1.2. Research application
6.5. Europe Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.5.1. Key Highlights
6.5.1.1. Human vaccine
6.5.1.2. Veterinary vaccine
6.6. Europe Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.6.1. Key Highlights
6.6.1.1. Adults
6.6.1.2. Pediatric
6.6.1.3. Others
6.7. Europe Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1. Key Highlights
6.7.1.1. Germany Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.2. Germany Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.3. Germany Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.4. Germany Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.5. Germany Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.6. Germany Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.7. Germany Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.8. U.K. Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.9. U.K. Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.10. U.K. Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.11. U.K. Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.12. U.K. Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.13. U.K. Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.14. France Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.15. France Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.16. France Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.17. France Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.18. France Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.19. France Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.20. Italy Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.21. Italy Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.22. Italy Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.23. Italy Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.24. Italy Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.25. Italy Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.26. Turkey Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.27. Turkey Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.28. Turkey Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.29. Turkey Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.30. Turkey Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.31. Turkey Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.32. Russia Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.33. Russia Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.34. Russia Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.35. Russia Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.36. Russia Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.37. Russia Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.38. Rest of Europe Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.39. Rest of Europe Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.40. Rest of Europe Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.41. Rest of Europe Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.42. Rest of Europe Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
6.7.1.43. Rest of Europe Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7. Asia Pacific Vaccine Adjuvant Market Outlook, 2019 - 2032
7.1. Asia Pacific Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Adjuvant emulsions
7.1.1.2. Particulate adjuvants
7.1.1.3. Combination adjuvants
7.1.1.4. Pathogen components
7.1.1.5. Carbohydrate adjuvants
7.1.1.6. Liposome adjuvants
7.1.1.7. Alum
7.1.1.8. Others
7.2. Asia Pacific Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Intramuscular route
7.2.1.2. Intranasal route
7.2.1.3. Intradermal route
7.2.1.4. Oral route
7.2.1.5. Subcutaneous route
7.2.1.6. Others
7.3. Asia Pacific Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. Cancer
7.3.1.2. Infectious diseases
7.3.1.3. Others
7.4. Asia Pacific Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.4.1. Key Highlights
7.4.1.1. Commercial application
7.4.1.2. Research application
7.5. Asia Pacific Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.5.1. Key Highlights
7.5.1.1. Human vaccine
7.5.1.2. Veterinary vaccine
7.6. Asia Pacific Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.6.1. Key Highlights
7.6.1.1. Adults
7.6.1.2. Pediatric
7.6.1.3. Others
7.7. Asia Pacific Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1. Key Highlights
7.7.1.1. China Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.2. China Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.3. China Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.4. China Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.5. China Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.6. China Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.7. Japan Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.8. Japan Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.9. Japan Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.10. Japan Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.11. Japan Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.12. Japan Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.13. South Korea Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.14. South Korea Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.15. South Korea Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.16. South Korea Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.17. South Korea Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.18. South Korea Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.19. India Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.20. India Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.21. India Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.22. India Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.23. India Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.24. India Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.25. Southeast Asia Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.26. Southeast Asia Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.27. Southeast Asia Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.28. Southeast Asia Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.29. Southeast Asia Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.30. Southeast Asia Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.31. Rest of Asia Pacific Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.32. Rest of Asia Pacific Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.33. Rest of Asia Pacific Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.34. Rest of Asia Pacific Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.35. Rest of Asia Pacific Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
7.7.1.36. Rest of Asia Pacific Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
8. Latin America Vaccine Adjuvant Market Outlook, 2019 - 2032
8.1. Latin America Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Adjuvant emulsions
8.1.1.2. Particulate adjuvants
8.1.1.3. Combination adjuvants
8.1.1.4. Pathogen components
8.1.1.5. Carbohydrate adjuvants
8.1.1.6. Liposome adjuvants
8.1.1.7. Alum
8.1.1.8. Others
8.2. Latin America Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Intramuscular route
8.2.1.2. Intranasal route
8.2.1.3. Intradermal route
8.2.1.4. Oral route
8.2.1.5. Subcutaneous route
8.2.1.6. Others
8.3. Latin America Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. Cancer
8.3.1.2. Infectious diseases
8.3.1.3. Others
8.4. Latin America Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.4.1. Key Highlights
8.4.1.1. Commercial application
8.4.1.2. Research application
8.5. Latin America Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.5.1. Key Highlights
8.5.1.1. Human vaccine
8.5.1.2. Veterinary vaccine
8.6. Latin America Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.6.1. Key Highlights
8.6.1.1. Adults
8.6.1.2. Pediatric
8.6.1.3. Others
8.7. Latin America Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1. Key Highlights
8.7.1.1. Brazil Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.2. Brazil Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.3. Brazil Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.4. Brazil Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.5. Brazil Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.6. Brazil Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.7. Mexico Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.8. Mexico Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.9. Mexico Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.10. Mexico Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.11. Mexico Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.12. Mexico Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.13. Argentina Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.14. Argentina Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.15. Argentina Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.16. Argentina Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.17. Argentina Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.18. Argentina Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.19. Rest of Latin America Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.20. Rest of Latin America Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.21. Rest of Latin America Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.22. Rest of Latin America Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.23. Rest of Latin America Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
8.7.1.24. Rest of Latin America Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9. Middle East & Africa Vaccine Adjuvant Market Outlook, 2019 - 2032
9.1. Middle East & Africa Vaccine Adjuvant Market Outlook, by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.1.1. Key Highlights
9.1.1.1. Adjuvant emulsions
9.1.1.2. Particulate adjuvants
9.1.1.3. Combination adjuvants
9.1.1.4. Pathogen components
9.1.1.5. Carbohydrate adjuvants
9.1.1.6. Liposome adjuvants
9.1.1.7. Alum
9.1.1.8. Others
9.2. Middle East & Africa Vaccine Adjuvant Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.2.1. Key Highlights
9.2.1.1. Intramuscular route
9.2.1.2. Intranasal route
9.2.1.3. Intradermal route
9.2.1.4. Oral route
9.2.1.5. Subcutaneous route
9.2.1.6. Others
9.3. Middle East & Africa Vaccine Adjuvant Market Outlook, by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.3.1. Key Highlights
9.3.1.1. Cancer
9.3.1.2. Infectious diseases
9.3.1.3. Others
9.4. Middle East & Africa Vaccine Adjuvant Market Outlook, by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.4.1. Key Highlights
9.4.1.1. Commercial application
9.4.1.2. Research application
9.5. Middle East & Africa Vaccine Adjuvant Market Outlook, by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.5.1. Key Highlights
9.5.1.1. Human vaccine
9.5.1.2. Veterinary vaccine
9.6. Middle East & Africa Vaccine Adjuvant Market Outlook, by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.6.1. Key Highlights
9.6.1.1. Adults
9.6.1.2. Pediatric
9.6.1.3. Others
9.7. Middle East & Africa Vaccine Adjuvant Market Outlook, by Country, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1. Key Highlights
9.7.1.1. GCC Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.2. GCC Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.3. GCC Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.4. GCC Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.5. GCC Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.6. GCC Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.7. South Africa Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.8. South Africa Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.9. South Africa Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.10. South Africa Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.11. South Africa Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.12. South Africa Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.13. Egypt Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.14. Egypt Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.15. Egypt Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.16. Egypt Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.17. Egypt Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.18. Egypt Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.19. Nigeria Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.20. Nigeria Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.21. Nigeria Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.22. Nigeria Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.23. Nigeria Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.24. Nigeria Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.25. Rest of Middle East & Africa Vaccine Adjuvant Market by Product Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.26. Rest of Middle East & Africa Vaccine Adjuvant Market by Route of Administration, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.27. Rest of Middle East & Africa Vaccine Adjuvant Market by Disease Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.28. Rest of Middle East & Africa Vaccine Adjuvant Market by Application, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.29. Rest of Middle East & Africa Vaccine Adjuvant Market by Vaccine Type, Value (US$ Bn) and Volume (Units), 2019 - 2032
9.7.1.30. Rest of Middle East & Africa Vaccine Adjuvant Market by End User, Value (US$ Bn) and Volume (Units), 2019 - 2032
10. Competitive Landscape
10.1. Company Market Share Analysis, 2025
10.2. Competitive Dashboard
10.3. Company Profiles
10.3.1. Pfizer Inc.
10.3.1.1. Company Overview
10.3.1.2. Product Portfolio
10.3.1.3. Financial Overview
10.3.1.4. Business Strategies and Development
10.3.2. GlaxoSmithKline plc
10.3.2.1. Company Overview
10.3.2.2. Product Portfolio
10.3.2.3. Financial Overview
10.3.2.4. Business Strategies and Development
10.3.3. AstraZeneca
10.3.3.1. Company Overview
10.3.3.2. Product Portfolio
10.3.3.3. Financial Overview
10.3.3.4. Business Strategies and Development
10.3.4. 3M
10.3.4.1. Company Overview
10.3.4.2. Product Portfolio
10.3.4.3. Financial Overview
10.3.4.4. Business Strategies and Development
10.3.5. Merck KGaA
10.3.5.1. Company Overview
10.3.5.2. Product Portfolio
10.3.5.3. Financial Overview
10.3.5.4. Business Strategies and Development
10.3.6. Adjuvatis
10.3.6.1. Company Overview
10.3.6.2. Product Portfolio
10.3.6.3. Financial Overview
10.3.6.4. Business Strategies and Development
10.3.7. Croda International Plc
10.3.7.1. Company Overview
10.3.7.2. Product Portfolio
10.3.7.3. Financial Overview
10.3.7.4. Business Strategies and Development
10.3.8. Novavax, Inc.
10.3.8.1. Company Overview
10.3.8.2. Product Portfolio
10.3.8.3. Financial Overview
10.3.8.4. Business Strategies and Development
10.3.9. InvivoGen
10.3.9.1. Company Overview
10.3.9.2. Product Portfolio
10.3.9.3. Financial Overview
10.3.9.4. Business Strategies and Development
10.3.10. Phibro Animal Health Corporation
10.3.10.1. Company Overview
10.3.10.2. Product Portfolio
10.3.10.3. Financial Overview
10.3.10.4. Business Strategies and Development
10.3.11. SEPPIC
10.3.11.1. Company Overview
10.3.11.2. Product Portfolio
10.3.11.3. Financial

Companies Mentioned

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • 3M
  • Merck KGaA
  • Adjuvatis
  • Croda International Plc
  • Novavax, Inc.
  • InvivoGen
  • Phibro Animal Health Corporation
  • SEPPIC
  • Agenus Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032 - Product Image

Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Vaccine Adjuvants Market by Product, Route of Administration, Disease, Application - Global Forecast 2025-2030 - Product Image

Vaccine Adjuvants Market by Product, Route of Administration, Disease, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine, Type - Global Forecast to 2029 - Product Image

Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine, Type - Global Forecast to 2029

  • Report
  • 389 Pages
  • Global
From
Aluminum Hydroxide Vaccine Adjuvants Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Aluminum Hydroxide Vaccine Adjuvants Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 86 Pages
  • Global
From
Vaccine Particulate Adjuvant Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Vaccine Particulate Adjuvant Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 104 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.